Pharmacology Quiz: Vitamin B12 Folate Therapy
20 questions · exam conditions
0:00
Vitamin B12 Folate TherapyQuestion 1 of 20

A 60-year-old patient who underwent a total gastrectomy 6 years ago presents with an unsteady gait and symmetric paresthesias in his feet. Based on the most likely underlying etiology, what finding would be expected on his complete blood count (CBC)?

An elevated mean corpuscular volume (MCV).
A decreased mean corpuscular volume (MCV).
Prominent basophilic stippling.
A normal MCV, as neurologic symptoms precede hematologic changes.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Vitamin B12 Folate Therapy

Practice Vitamin B12 Folate Therapy in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Vitamin B12 Folate Therapy, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 60-year-old patient who underwent a total gastrectomy 6 years ago presents with an unsteady gait and symmetric paresthesias in his feet. Based on the most likely underlying etiology, what finding would be expected on his complete blood count (CBC)?

  1. An elevated mean corpuscular volume (MCV). (correct answer)
  2. A decreased mean corpuscular volume (MCV).
  3. Prominent basophilic stippling.
  4. A normal MCV, as neurologic symptoms precede hematologic changes.
Explanation: A total gastrectomy removes gastric parietal cells, the sole source of intrinsic factor, which is essential for vitamin B12 absorption. This leads to B12 deficiency over several years as liver stores are depleted. Vitamin B12 deficiency causes both subacute combined degeneration of the spinal cord (neurologic symptoms) and megaloblastic anemia. The hallmark of megaloblastic anemia on a CBC is macrocytosis, which is an elevated MCV (>100 fL).

Question 2

A 68-year-old male with a history of alcohol use disorder presents with fatigue. Lab results show Hb 9.5 g/dL, MCV 115 fL, serum folate 2.1 ng/mL (normal >4.0), and serum B12 155 pg/mL (normal >200). He is diagnosed with megaloblastic anemia. What is the most appropriate initial pharmacotherapeutic management?

  1. Initiate high-dose oral folic acid and re-evaluate B12 status in one month.
  2. Administer parenteral vitamin B12 initially, followed by oral folic acid after one week.
  3. Administer parenteral vitamin B12 and oral folic acid concurrently. (correct answer)
  4. Prescribe leucovorin to bypass the metabolic block and begin oral B12.
Explanation: In a patient with megaloblastic anemia and documented deficiency of both vitamin B12 and folate, it is critical to replete both vitamins. Administering folate alone can correct the anemia but will not address the B12 deficiency, potentially allowing for the progression of irreversible neurological damage. Therefore, concurrent administration of parenteral B12 (to ensure absorption) and oral folic acid is the standard of care.

Question 3

A 78-year-old patient with stage 4 chronic kidney disease (eGFR 25 mL/min/1.73m²) is found to have macrocytic anemia. Serum B12 and folate levels are within the normal range. However, the serum methylmalonic acid (MMA) level is significantly elevated. What is the most likely explanation for this isolated finding?

  1. The patient has a functional B12 deficiency not detected by the serum assay.
  2. Uremia is interfering with the MMA laboratory assay, causing a false positive.
  3. Impaired renal clearance of MMA is leading to its accumulation in the serum. (correct answer)
  4. The anemia is caused by erythropoietin deficiency, which also raises MMA.
Explanation: Methylmalonic acid (MMA) is primarily cleared by the kidneys. In patients with significant renal impairment (chronic kidney disease), renal clearance of MMA is reduced, leading to its accumulation in the blood. Therefore, an elevated MMA level is not a specific marker for vitamin B12 deficiency in this population and must be interpreted with caution. Anemia in CKD is most often due to erythropoietin deficiency, but the macrocytosis prompted the B12/folate workup.

Question 4

A patient receiving high-dose methotrexate for acute lymphoblastic leukemia develops severe oral mucositis and pancytopenia. Which of the following agents is specifically indicated for rescue therapy to mitigate these toxic effects?

  1. High-dose folic acid
  2. Parenteral cyanocobalamin
  3. Leucovorin (folinic acid) (correct answer)
  4. Pyridoxine (vitamin B6)
Explanation: Methotrexate inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to the active tetrahydrofolate. This depletes the folate cofactors necessary for DNA synthesis, leading to toxicity in rapidly dividing cells. Leucovorin (folinic acid) is a reduced form of folate that is downstream of the DHFR-catalyzed step, allowing it to replenish the tetrahydrofolate pool and 'rescue' normal cells from methotrexate's effects. Standard folic acid would be ineffective as its activation is blocked.

Question 5

Patients with chronic hemolytic anemias, such as sickle cell disease or hereditary spherocytosis, are often prescribed daily folic acid supplements. This recommendation is based on an increased risk of deficiency due to which of the following processes?

  1. Increased urinary excretion of folate due to renal damage.
  2. Impaired intestinal absorption of dietary folate.
  3. Drug interactions with hydroxyurea, which depletes folate.
  4. Increased consumption of folate for compensatory erythropoiesis. (correct answer)
Explanation: When you encounter questions about nutritional deficiencies in chronic diseases, think about which nutrients are consumed during the body's compensatory responses to the underlying pathology. In chronic hemolytic anemias like sickle cell disease and hereditary spherocytosis, red blood cells are destroyed at an accelerated rate. To compensate for this ongoing hemolysis, the bone marrow dramatically increases red blood cell production (erythropoiesis). This process requires substantial amounts of folate, a B-vitamin essential for DNA synthesis during cell division. The faster the bone marrow produces new RBCs, the more folate it consumes, eventually depleting the body's stores and creating a functional deficiency despite adequate dietary intake. Option A incorrectly suggests renal damage causes folate loss through urine. While some hemolytic anemias can affect kidneys, folate deficiency primarily results from increased consumption, not urinary losses. Option B proposes impaired absorption, but these conditions don't typically damage the small intestine where folate is absorbed. Option C mentions hydroxyurea interactions—while this drug is used in sickle cell disease, folate deficiency occurs even in patients not taking hydroxyurea, making increased consumption the fundamental mechanism. The key insight is recognizing that chronic hemolytic conditions create a hypermetabolic state in the bone marrow. Remember this pattern: whenever you see chronic hemolysis paired with nutritional deficiencies, think about nutrients required for accelerated cell production—folate for DNA synthesis, iron for hemoglobin, and sometimes B12 for cell maturation.

Question 6

A 55-year-old patient with a long history of Crohn's disease primarily affecting the terminal ileum presents with megaloblastic anemia and symmetric paresthesias in the lower extremities. Which pattern of metabolic intermediates is most consistent with this patient's underlying deficiency?

  1. Normal methylmalonic acid (MMA), elevated homocysteine.
  2. Elevated MMA, normal homocysteine.
  3. Elevated MMA, elevated homocysteine. (correct answer)
  4. Normal MMA, normal homocysteine.
Explanation: Crohn's disease of the terminal ileum impairs the absorption of vitamin B12. Vitamin B12 is a required cofactor for two key reactions: the conversion of methylmalonyl-CoA to succinyl-CoA (via methylmalonyl-CoA mutase) and the conversion of homocysteine to methionine (via methionine synthase). Deficiency of B12 causes a block in both pathways, leading to an accumulation and elevation of both MMA and homocysteine.

Question 7

Chronic abuse of nitrous oxide (N₂O) can induce a myeloneuropathy identical to that seen in subacute combined degeneration of the spinal cord. This toxicity is mediated through which of the following biochemical mechanisms?

  1. Nitrous oxide irreversibly oxidizes the cobalt ion of vitamin B12, rendering it inactive. (correct answer)
  2. Nitrous oxide directly damages myelin-producing oligodendrocytes.
  3. Nitrous oxide competitively inhibits the intestinal absorption of vitamin B12.
  4. Nitrous oxide chelates copper, leading to a deficiency state that mimics B12 deficiency.
Explanation: When you encounter questions about nitrous oxide toxicity and myeloneuropathy, think about vitamin B12 metabolism and how anesthetics can interfere with essential cofactor functions. Nitrous oxide causes neurological damage through a specific mechanism involving vitamin B12 inactivation. N₂O irreversibly oxidizes the cobalt ion in vitamin B12 from its active Co⁺ form to the inactive Co²⁺ or Co³⁺ forms. This renders the vitamin functionally useless as a cofactor for methionine synthase and methylmalonyl-CoA mutase, leading to the same biochemical consequences as B12 deficiency. The result is subacute combined degeneration of the spinal cord, characterized by demyelination of the posterior and lateral columns. This explains why answer choice A is correct. Looking at the incorrect options: B is wrong because nitrous oxide doesn't directly damage oligodendrocytes—the damage is indirect through B12 inactivation. C is incorrect because the mechanism isn't about absorption; patients can have normal B12 levels but the vitamin is simply non-functional due to cobalt oxidation. D describes a copper deficiency mechanism, which can cause similar neurological symptoms but isn't the pathway involved with nitrous oxide toxicity. Remember this pattern: when you see nitrous oxide causing B12-like deficiency symptoms, think "oxidation of cobalt ion" rather than true B12 deficiency. This is a classic example of how drugs can interfere with cofactor function at the molecular level, making vitamins present but inactive.

Question 8

A 65-year-old male is evaluated for progressive cognitive decline over the past year. Lab work reveals a high MCV of 112 fL and a profoundly low serum B12 of 90 pg/mL. After one month of aggressive parenteral B12 therapy, his anemia and MCV have normalized, but his cognitive function shows only minimal improvement. What is the most likely explanation for this discrepancy in response?

  1. The cognitive symptoms were due to an unrelated dementia, and the B12 deficiency was an incidental finding.
  2. The patient requires a switch to hydroxocobalamin, as cyanocobalamin has poor CNS penetration.
  3. The patient has a concurrent folate deficiency that is now unmasked and requires treatment.
  4. Neurologic damage from prolonged vitamin B12 deficiency can be partially or completely irreversible. (correct answer)
Explanation: When evaluating vitamin B12 deficiency, you need to understand that hematologic and neurologic manifestations respond differently to treatment. The hematologic effects (anemia, elevated MCV) typically resolve quickly with adequate B12 replacement, while neurologic damage may be partially or completely irreversible depending on the duration and severity of deficiency. This patient's rapid hematologic recovery with persistent cognitive impairment illustrates a key principle: prolonged B12 deficiency causes demyelination and axonal damage in the nervous system that cannot always be reversed, even with aggressive treatment. The fact that his anemia normalized confirms adequate B12 replacement and absorption, making the irreversible neurologic damage (option D) the most likely explanation. Option A is incorrect because the temporal relationship between B12 deficiency and cognitive decline, plus the severe deficiency level (90 pg/mL), strongly suggests B12-related neurologic damage rather than coincidental dementia. Option B misunderstands cobalamin pharmacology—both cyanocobalamin and hydroxocobalamin effectively cross the blood-brain barrier and treat neurologic B12 deficiency equally well. Option C doesn't fit the clinical picture; folate deficiency would cause persistent hematologic abnormalities (continued elevated MCV and anemia), which this patient doesn't have. Remember this pattern: in B12 deficiency cases, hematologic improvement without neurologic recovery suggests irreversible damage from prolonged deficiency. Early recognition and treatment of B12 deficiency is crucial because neurologic damage becomes increasingly irreversible with time—a critical concept for both clinical practice and pharmacology exams.

Question 9

A patient presents with macrocytic anemia. Laboratory evaluation reveals a low serum folate level. Serum B12 is in the low-normal range. Serum homocysteine is markedly elevated, but serum methylmalonic acid (MMA) is normal. Which diagnosis do these findings most specifically support?

  1. Combined folate and vitamin B12 deficiency.
  2. Anemia of chronic kidney disease.
  3. Isolated folate deficiency. (correct answer)
  4. Isolated vitamin B12 deficiency.
Explanation: This pattern of lab results is classic for isolated folate deficiency. Both folate and B12 are required for the conversion of homocysteine to methionine, so homocysteine is elevated in either deficiency. However, only B12 is required for the conversion of methylmalonyl-CoA to succinyl-CoA. Therefore, an elevated MMA level is specific to B12 deficiency. A normal MMA with elevated homocysteine points specifically to folate deficiency as the cause.

Question 10

A patient develops megaloblastic anemia while being treated with trimethoprim for a urinary tract infection. Supplementation with standard oral folic acid proves ineffective. Which of the following agents would be the most appropriate therapy to correct this patient's anemia?

  1. High-dose cyanocobalamin
  2. Leucovorin (correct answer)
  3. Oral ferrous sulfate
  4. Pyridoxine
Explanation: Trimethoprim, like methotrexate, is an inhibitor of dihydrofolate reductase (DHFR), although it has greater selectivity for the bacterial enzyme. By inhibiting human DHFR, it can induce megaloblastic anemia by blocking the activation of folic acid to its usable form, tetrahydrofolate. Leucovorin (folinic acid) is an already reduced form of folate that can bypass the DHFR enzymatic block, thereby repleting the folate pool and correcting the anemia.

Question 11

What is the primary pharmacological advantage of using parenteral hydroxocobalamin compared to cyanocobalamin for the treatment of vitamin B12 deficiency?

  1. It is significantly less painful upon intramuscular injection.
  2. It is more extensively protein-bound, resulting in a longer duration of action. (correct answer)
  3. It has superior penetration across the blood-brain barrier.
  4. It directly provides methylcobalamin, bypassing one metabolic step.
Explanation: The main difference between hydroxocobalamin and cyanocobalamin is their protein binding. Hydroxocobalamin binds more avidly to plasma proteins and is retained in the body for a longer period. This results in a longer half-life and allows for less frequent dosing intervals during maintenance therapy compared to cyanocobalamin.

Question 12

A 75-year-old patient with newly diagnosed pernicious anemia is initiated on intramuscular cyanocobalamin therapy. Which of the following laboratory parameters provides the earliest evidence of a therapeutic response in the bone marrow?

  1. A decrease in serum methylmalonic acid (MMA) levels.
  2. An increase in the peripheral reticulocyte count. (correct answer)
  3. Normalization of the mean corpuscular volume (MCV).
  4. A rise in the serum hemoglobin concentration.
Explanation: The earliest indicator of a bone marrow response to vitamin B12 therapy in megaloblastic anemia is an increase in the reticulocyte count, known as reticulocytosis. This typically occurs within 2 to 5 days of initiating treatment as the bone marrow rapidly begins producing new red blood cells. Hemoglobin levels begin to rise after the reticulocyte peak, and normalization of the MCV takes several weeks to months as the macrocytic cells are gradually replaced.

Question 13

A 68-year-old male with a history of alcohol use disorder presents with fatigue. Lab results show Hb 9.5 g/dL, MCV 115 fL, serum folate 2.1 ng/mL (normal >4.0), and serum B12 155 pg/mL (normal >200). He is diagnosed with megaloblastic anemia. What is the most appropriate initial pharmacotherapeutic management?

  1. Initiate high-dose oral folic acid and re-evaluate B12 status in one month.
  2. Administer parenteral vitamin B12 initially, followed by oral folic acid after one week.
  3. Administer parenteral vitamin B12 and oral folic acid concurrently. (correct answer)
  4. Prescribe leucovorin to bypass the metabolic block and begin oral B12.
Explanation: In a patient with megaloblastic anemia and documented deficiency of both vitamin B12 and folate, it is critical to replete both vitamins. Administering folate alone can correct the anemia but will not address the B12 deficiency, potentially allowing for the progression of irreversible neurological damage. Therefore, concurrent administration of parenteral B12 (to ensure absorption) and oral folic acid is the standard of care.

Question 14

A patient receiving high-dose methotrexate for acute lymphoblastic leukemia develops severe oral mucositis and pancytopenia. Which of the following agents is specifically indicated for rescue therapy to mitigate these toxic effects?

  1. High-dose folic acid
  2. Parenteral cyanocobalamin
  3. Leucovorin (folinic acid) (correct answer)
  4. Pyridoxine (vitamin B6)
Explanation: Methotrexate inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to the active tetrahydrofolate. This depletes the folate cofactors necessary for DNA synthesis, leading to toxicity in rapidly dividing cells. Leucovorin (folinic acid) is a reduced form of folate that is downstream of the DHFR-catalyzed step, allowing it to replenish the tetrahydrofolate pool and 'rescue' normal cells from methotrexate's effects. Standard folic acid would be ineffective as its activation is blocked.

Question 15

A 60-year-old patient who underwent a total gastrectomy 6 years ago presents with an unsteady gait and symmetric paresthesias in his feet. Based on the most likely underlying etiology, what finding would be expected on his complete blood count (CBC)?

  1. An elevated mean corpuscular volume (MCV). (correct answer)
  2. A decreased mean corpuscular volume (MCV).
  3. Prominent basophilic stippling.
  4. A normal MCV, as neurologic symptoms precede hematologic changes.
Explanation: A total gastrectomy removes gastric parietal cells, the sole source of intrinsic factor, which is essential for vitamin B12 absorption. This leads to B12 deficiency over several years as liver stores are depleted. Vitamin B12 deficiency causes both subacute combined degeneration of the spinal cord (neurologic symptoms) and megaloblastic anemia. The hallmark of megaloblastic anemia on a CBC is macrocytosis, which is an elevated MCV (>100 fL).

Question 16

A patient presents with macrocytic anemia. Laboratory evaluation reveals a low serum folate level. Serum B12 is in the low-normal range. Serum homocysteine is markedly elevated, but serum methylmalonic acid (MMA) is normal. Which diagnosis do these findings most specifically support?

  1. Combined folate and vitamin B12 deficiency.
  2. Anemia of chronic kidney disease.
  3. Isolated folate deficiency. (correct answer)
  4. Isolated vitamin B12 deficiency.
Explanation: This pattern of lab results is classic for isolated folate deficiency. Both folate and B12 are required for the conversion of homocysteine to methionine, so homocysteine is elevated in either deficiency. However, only B12 is required for the conversion of methylmalonyl-CoA to succinyl-CoA. Therefore, an elevated MMA level is specific to B12 deficiency. A normal MMA with elevated homocysteine points specifically to folate deficiency as the cause.

Question 17

A patient develops megaloblastic anemia while being treated with trimethoprim for a urinary tract infection. Supplementation with standard oral folic acid proves ineffective. Which of the following agents would be the most appropriate therapy to correct this patient's anemia?

  1. High-dose cyanocobalamin
  2. Leucovorin (correct answer)
  3. Oral ferrous sulfate
  4. Pyridoxine
Explanation: Trimethoprim, like methotrexate, is an inhibitor of dihydrofolate reductase (DHFR), although it has greater selectivity for the bacterial enzyme. By inhibiting human DHFR, it can induce megaloblastic anemia by blocking the activation of folic acid to its usable form, tetrahydrofolate. Leucovorin (folinic acid) is an already reduced form of folate that can bypass the DHFR enzymatic block, thereby repleting the folate pool and correcting the anemia.

Question 18

Chronic abuse of nitrous oxide (N₂O) can induce a myeloneuropathy identical to that seen in subacute combined degeneration of the spinal cord. This toxicity is mediated through which of the following biochemical mechanisms?

  1. Nitrous oxide irreversibly oxidizes the cobalt ion of vitamin B12, rendering it inactive. (correct answer)
  2. Nitrous oxide directly damages myelin-producing oligodendrocytes.
  3. Nitrous oxide competitively inhibits the intestinal absorption of vitamin B12.
  4. Nitrous oxide chelates copper, leading to a deficiency state that mimics B12 deficiency.
Explanation: When you encounter questions about nitrous oxide toxicity and myeloneuropathy, think about vitamin B12 metabolism and how anesthetics can interfere with essential cofactor functions. Nitrous oxide causes neurological damage through a specific mechanism involving vitamin B12 inactivation. N₂O irreversibly oxidizes the cobalt ion in vitamin B12 from its active Co⁺ form to the inactive Co²⁺ or Co³⁺ forms. This renders the vitamin functionally useless as a cofactor for methionine synthase and methylmalonyl-CoA mutase, leading to the same biochemical consequences as B12 deficiency. The result is subacute combined degeneration of the spinal cord, characterized by demyelination of the posterior and lateral columns. This explains why answer choice A is correct. Looking at the incorrect options: B is wrong because nitrous oxide doesn't directly damage oligodendrocytes—the damage is indirect through B12 inactivation. C is incorrect because the mechanism isn't about absorption; patients can have normal B12 levels but the vitamin is simply non-functional due to cobalt oxidation. D describes a copper deficiency mechanism, which can cause similar neurological symptoms but isn't the pathway involved with nitrous oxide toxicity. Remember this pattern: when you see nitrous oxide causing B12-like deficiency symptoms, think "oxidation of cobalt ion" rather than true B12 deficiency. This is a classic example of how drugs can interfere with cofactor function at the molecular level, making vitamins present but inactive.

Question 19

A patient with pernicious anemia is prescribed a regimen of IM cyanocobalamin, 1000 mcg daily for the first week, followed by weekly and then monthly injections. What is the primary rationale for administering these initial daily high-dose 'loading' injections?

  1. To rapidly reverse the patient's neurologic symptoms.
  2. To overcome competitive inhibition by anti-intrinsic factor antibodies.
  3. To stimulate the gastric parietal cells to produce new intrinsic factor.
  4. To saturate transcobalamin and replete depleted hepatic stores of vitamin B12. (correct answer)
Explanation: When you encounter questions about vitamin B12 therapy in pernicious anemia, focus on the underlying pathophysiology and the body's vitamin B12 storage system. Pernicious anemia results from autoimmune destruction of gastric parietal cells, leading to intrinsic factor deficiency and subsequent B12 malabsorption. The primary goal of high-dose loading injections is to saturate transcobalamin (the transport protein) and rapidly replete the severely depleted hepatic stores of vitamin B12. The liver normally stores 2-5 mg of B12, representing several years' worth of supply. In pernicious anemia, these stores become critically depleted over time. Daily high-dose injections bypass the absorption problem entirely and quickly restore these vital reserves, which are essential for ongoing cellular metabolism. Let's examine why the other options are incorrect: Option A is tempting since neurologic symptoms are serious, but while high-dose therapy does help neurologic symptoms, the primary rationale is store repletion rather than symptom reversal speed. Option B misunderstands the mechanism – you're bypassing the GI tract entirely with IM injections, so competitive inhibition by antibodies is irrelevant. Option C reflects a fundamental misunderstanding – pernicious anemia involves autoimmune destruction of parietal cells, and B12 cannot stimulate regeneration of these damaged cells. Remember this key principle: loading doses in vitamin deficiency states are primarily about rapidly restoring tissue stores, not just correcting serum levels. Think "fill the tank first" when you see loading dose regimens for fat-soluble vitamins or B12.

Question 20

A 65-year-old male is evaluated for progressive cognitive decline over the past year. Lab work reveals a high MCV of 112 fL and a profoundly low serum B12 of 90 pg/mL. After one month of aggressive parenteral B12 therapy, his anemia and MCV have normalized, but his cognitive function shows only minimal improvement. What is the most likely explanation for this discrepancy in response?

  1. The cognitive symptoms were due to an unrelated dementia, and the B12 deficiency was an incidental finding.
  2. The patient requires a switch to hydroxocobalamin, as cyanocobalamin has poor CNS penetration.
  3. The patient has a concurrent folate deficiency that is now unmasked and requires treatment.
  4. Neurologic damage from prolonged vitamin B12 deficiency can be partially or completely irreversible. (correct answer)
Explanation: When evaluating vitamin B12 deficiency, you need to understand that hematologic and neurologic manifestations respond differently to treatment. The hematologic effects (anemia, elevated MCV) typically resolve quickly with adequate B12 replacement, while neurologic damage may be partially or completely irreversible depending on the duration and severity of deficiency. This patient's rapid hematologic recovery with persistent cognitive impairment illustrates a key principle: prolonged B12 deficiency causes demyelination and axonal damage in the nervous system that cannot always be reversed, even with aggressive treatment. The fact that his anemia normalized confirms adequate B12 replacement and absorption, making the irreversible neurologic damage (option D) the most likely explanation. Option A is incorrect because the temporal relationship between B12 deficiency and cognitive decline, plus the severe deficiency level (90 pg/mL), strongly suggests B12-related neurologic damage rather than coincidental dementia. Option B misunderstands cobalamin pharmacology—both cyanocobalamin and hydroxocobalamin effectively cross the blood-brain barrier and treat neurologic B12 deficiency equally well. Option C doesn't fit the clinical picture; folate deficiency would cause persistent hematologic abnormalities (continued elevated MCV and anemia), which this patient doesn't have. Remember this pattern: in B12 deficiency cases, hematologic improvement without neurologic recovery suggests irreversible damage from prolonged deficiency. Early recognition and treatment of B12 deficiency is crucial because neurologic damage becomes increasingly irreversible with time—a critical concept for both clinical practice and pharmacology exams.